differences at the time of ICU admission? How will that be done? What will the statistical model look like? Related to my previous comments: The Data analysis plan suggests that only univariable analyses will be conducted. Why not consider e.g. regression-bases analyses to account for differences between VAP and non-VAP cases? Regarding the sample size: if the authors really don't have a clue whether 320 cases will provide any chance of being able to draw conclusions, why proceed anyway? But probably they feel quite comfortable. At least, could they indicate whether the number of cases is comparable to earlier studies?
REVIEWER
Arthur CW Lau Hong Kong, China REVIEW RETURNED 13-Mar-2018
GENERAL COMMENTS Nil

REVIEWER
Valério Monteiro-Neto Universidade Ceuma, Brazil REVIEW RETURNED 26-May-2018
GENERAL COMMENTS
This protocol will address a still challenging and very important issue in hospital settings -the diagnosis of VAP, but in a non-tertiary Australian regional ICU. A retrospective survey will be performed to establish some clinical and epidemiological features, such as its incidence, case characteristics and outcomes, including mortality and length of hospital stay related to VAP. There is a clear description of the overall protocol. Strengths of the study include the investigation of VAP impact in a small regional hospital with distinct aspects from metropolitan hospitals and the potential to verify under-or over-reporting of VAP due to distinct diagnostic criteria (checklist based identification versus consultant-based diagnosis of VAP). The major limitation is the small number of expected patients to be enrolled, which might affect the study interpretation and would not lead to valuable data for the benefit of the patient in the future. Although microbial growth was excluded as an additional VAP diagnostic criteria, microbiology analysis is helpful to determine antibiotic regimen changes and also to establish local prevalence and the antimicrobial susceptibility profile of the usual pathogens, since data from guidelines or other hospitals can be ineffective. We would like to thank the reviewers for their constructive and helpful comments. We have addressed all reviewer comments below and included any major additions/changes to the manuscript in italics. All changes are included as track changes in the resubmitted manuscript. We consider the manuscript greatly improved because of these changes, and we thank you for that.
VERSION 1 -AUTHOR RESPONSE
# Editor's and Reviewers' comments
Authors' responses Editor
1.
Please provide some timelines for the project. What is the current status? When you do you think the study will be completed?
We have now added the following text in the manuscript.
Lines 229-230: "We expect to complete data extraction in September 2018 and aim to complete the study 12 months later."
Reviewer 2
2.
At several occasions, notably in the introduction, it is made clear that tertiary and non-tertiary patient populations likely differ. Will the researchers take any actions towards a formal comparison between the characteristics of their patients and the populations described in the literature, in terms of the APACHE score, say?
A formal comparison between patient populations from a tertiary facility and our study is not possible as our data collection does not include data from a tertiary facility.
Comparison of characteristics (e.g. age, sex, APACHE scores) between our cohort and that of previously published literature from tertiary facilities (e.g. Elliott et al., 2015) will take place within the discussion of our intended manuscript.
3.
I think the statement under the fourth bullet point on strengths and limitations is odd. The low number of cases will not affect generalizability itself, it may simply be that the results of this study are rather uninformative. Consider deleting the comment about safe and generalizable conclusions.
In light of the reviewer's comment we have deleted the fourth bullet point on the strengths and limitations. The reviewer highlights an interesting point which has been considered in depth. Our data collection period was specifically selected to minimise policy and software changes within the hospital Intensive Care Unit (ICU). For instance, the clinical information system currently used was implemented in the ICU circa June 2012. The study period (i.e. start of 2013) was chosen to ensure reliable, consistent and standardised data collection (allowing a 6 month grace period for staff to become adept at the new system). In addition, no major policy changes concerning VAP were implemented within ICU during the study timeframe.
5.
Page 9. Description of the analysis for aim 4 mentions crude and adjusted mortality rates. What does the adjustment look like? Which variables will be adjusted for? What kind of statistical model will be used?
We thank the reviewer for raising this issue. We have now provided relevant clarifications in the manuscript.
Lines 194, 202-203: "Adjusted mortality rates for VAP and non-VAP cases will be computed through Poisson risk model with robust variance estimate adjusted for APACHE II score and Charlson Comorbidities Index on admission."
6.
Also, who are the non-VAP cases?
Non-VAP cases are those who did not develop VAP either through the checklist definition or through the consultantbased diagnosis. We describe the process for identifying VAP and non-VAP cases in the Case Identification section of the manuscript.
We have now further clarified that: We agree with the reviewer that analysis of actual hospital charges from VAP onset to discharge from hospital would have been more meaningful and useful. Unfortunately, we cannot extract these data from the hospital records. That is why we planned to use blanket costs for each department, rather than actual hospital charges. We realise that using blanket costs for each department (Aim 6) does not provide much additional information as compared to reporting length of stay (Aim 5). Based on the above, we decided to exclude analysis of healthcare costs from our protocol. We have therefore deleted Aim 6 and all other references to analysis of healthcare costs from our protocol. 
9.
Regarding the sample size: if the authors really don't have a clue whether 320 cases will provide any chance of being able to draw conclusions, why proceed anyway? But probably they feel quite comfortable. At least, could they indicate whether the number of cases is comparable to earlier studies?
The study design limits our ability to accurately calculate our sample size a priori, however we estimate a sample of 320 cases over the data collection period. This is considerably larger than previously published evidence investigating VAP, with a sample size of n=169 (Elliott et al., 2015) . The following text has been inserted on Line 173.
Lines 180-181: "Our estimated sample size is comparable with previous published literature regarding VAP within a tertiary facility (Elliott, et al. 6 )."
Nil comments
We thank the reviewer for reading our manuscript.
Reviewer 3
11. The major limitation is the small number of expected patients to be enrolled, which might affect the study interpretation and would not lead to valuable data for the benefit of the patient in the As mentioned in reviewer comment number 7, this study is in line with previously published evidence investigating VAP, with a sample size of n=169 (Elliott et al., 2015) . The following text has been inserted on Line 173.
future.
12.
Although microbial growth was excluded as an additional VAP diagnostic criteria, microbiology analysis is helpful to determine antibiotic regimen changes and also to establish local prevalence and the antimicrobial susceptibility profile of the usual pathogens, since data from guidelines or other hospitals can be ineffective.
We agree that microbial growth is an important component to establish information about the local prevalence of pathogens. To this end we have included in our protocol manuscript that microbiology related to VAP will be recorded as part of the characteristics. This is described on line 156 of the manuscript. 
GENERAL COMMENTS
The authors have improved and clarified the manuscript. I have no further comments.
